High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

AIDS

Volumn 15, Issue 9, 2001, Pages 1089-1095

  Veldkamp, Agnes I ^a   Weverling, Gerrit J ^b   Lange, Joep M A ^b   Montaner, Julio S G ^c   Reiss, Peter ^b   Cooper, David A ^d   Vella, Stefano ^e   Hall, David ^f   Beijnen, Jos H ^a   Hoetelmans, Richard M W ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Nevirapine; Pharmacokinetics; Virological response

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; NEVIRAPINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS LOAD;

ANTI-HIV AGENTS; DIDANOSINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; NEVIRAPINE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 0035876184     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200106150-00003     Document Type: Article

References (12)

1. Nevirapine: A review of its development, pharmacological profile and potential for clinical use
2. High-dose nevirapine in previously untreated human immunodeficiency virus type-1 infected persons does not result in sustained suppression of viral replication
3. High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection
4. Plasma concentrations of saquinavir (SQV) determine HIV-1 RNA response over a 48-week period
5. Antiviral effect and pharmacokinetic interactions between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1
6. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple therapy
7. A randomised, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS Trial
8. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 in plasma: Application to acute retroviral infection
9. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: Enhanced sensitivity
10. HPLC-UV method for the quantitation of nevirapine in biological matrices following solid phase extraction
11. Population pharmacokinetics of efavirenz in phase II studies and relationships with efficacy
12. Can the total systemic exposure to nevirapine in HIV-1-infected individuals be predicted by a single plasma concentration?